Navigation Links
Oncology Alliance: Apeiron, CCRI and SIOPEN Join Forces Against Neuroblastoma
Date:6/22/2011

VIENNA, June 22, 2011 /PRNewswire/ --


 

Vienna based biotech company APEIRON Biologics AG (Apeiron) strengthens its oncology pipeline: The company will support the clinical development of an immune therapy against high-risk neuroblastoma that is being conducted by the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). It is presently under investigation in a phase III trial across various European clinical centers. In return, Apeiron obtains the rights to file for regulatory approval and to market the final product. The approach is based on a monoclonal antibody (ch14.18) and constitutes Apeiron's most advanced project. It also marks another milestone for the company and its development strategy to treat neuroblastoma. This strategy was initiated earlier this year with the licensing of a clinical phase II project from Merck KGaA.

Today, Vienna based Apeiron announced the conclusion of an agreement with the Children's Cancer Research Institute (CCRI) and the European Neuroblastoma Research Network (SIOPEN). Thereby, Apeiron obtains the rights to further develop, file for regulatory approval and market the antibody ch14.18. This monoclonal antibody exhibits therapeutic effect against high-risk neuroblastoma, an aggressive form of infant cancer. The antibody specifically targets the antigen GD2, a feature on the surface of neuroblastoma cells and thereby initiates an immune reaction against these cells.

As part of the agreement, Apeiron will provide substantial support for an ongoing European clinical phase III trial with ch14.18. Due to the limited number of clinical centers specializing in the treatment of high-risk neuroblastoma, Apeiron is considering marketing the therapy on its own.

The Austrian company Polymun Scientific, a long-time business partner of Apeiron, has already been producing clinical supplies for the CCRI/SIOPEN spo
'/>"/>

SOURCE APEIRON Biologics AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
2. Cell Therapeutics Completes Type A Meeting With FDAs Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
3. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
4. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
5. Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology
6. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
7. Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic
8. Translational Sciences Corporation to Launch OncoTracâ„¢ at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
10. Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise
11. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 Steven Rash , the CEO ... its operating subsidiary American Seed & Oil Company, presented ... investors yesterday in New York City.  Mr. Rash,s presentation ... American Seed & Oil Company has recently announced the ... Hemp Seed Foods , the EpiVape , and ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) has announced ... in 2014 - a Perspective of Mental Health Patient ... For the first time, in 2014, the ... the pharmaceutical industry held by patient groups with an ... organisations representing all therapy areas. - Findings ...
(Date:4/16/2015)... April 16, 2015 Mindray Medical International ... and marketer of medical devices worldwide, announced today ... Exchange Commission an Annual Report on Form 20-F that ... 31, 2014. An electronic version of Mindray,s Annual ... investor relations website at  http://ir.mindray.com  or  http://www.sec.gov . ...
Breaking Medicine Technology:American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
... May 22 Shire plc (LSE: SHP, Nasdaq: ... results of a study showing that coadministration of the ADHD ... (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did ... concentration of d -amphetamine to be reached in the ...
... Calif., May 21 Telik, Inc. (Nasdaq: TELK ... study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal ... annual meeting of the American Society of Clinical Oncology (ASCO) ... in Orlando, FL.Details of the presentation are as follows:, ...
Cached Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
(Date:4/17/2015)... 17, 2015 Most dental patients are ... units are made overseas by foreign dental laboratories, according ... remain unregulated in more than 40 states by their ... Association of Dental Laboratories has created the ... among patients about the consequences that could be associated ...
(Date:4/17/2015)... Baptist Health and The University of Texas MD ... to transform oncology care in northeast Florida and southeast ... a joint cancer program to enhance patient access to ... Anderson Cancer Center is anticipated to open in the ... coordinated, multidisciplinary cancer care for adults in the region. ...
(Date:4/17/2015)... April 17, 2015 Scientists from ... multicenter team of U.S. and Venezuelan researchers, have ... in humans among an isolated tribe of Yanomami ... Bacterial diversity in the Yanomami, previously unexposed to ... nearly double that of people living in industrialized ...
(Date:4/17/2015)... Connie Casad, M.D., a well-known and ... with 30 years of practice experience in Dallas, Texas, ... of service for her patients with the availability of ... wellness books with a brief synopsis on each for ... interest in providing this service, Dr. Casad said, “Furnishing ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog post ... insurance quotes . , The online environment can ... cars. Drivers should always compare multiple car insurance policies ... is a competitive one, which means that customers can ... It is now possible to compare online car insurance ...
Breaking Medicine News(10 mins):Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:The Best Auto Insurance Quotes Are Available Online! 2
... entirely online, announces participation of Dr. Larry Kaskel, Founder and Medical ... "Improved Patient Outcomes and Enhanced Revenue with Therapeutic Lifestyle Changes." ... ... CardioCareLive , the first of its kind online medical conference ...
... Economic Climate and Exceptional Events, - Operating Profitability Has Resisted Well, - Continued Reduction in Net Debt, ... 2007, Net sales ... 19.3 ... 11.5% 14.5%, Current operating income* ...
... NEW YORK, Feb. 18 The Michael J. ... million total to six teams working to develop ... visualize the clumping of the alpha-synuclein protein in ... accelerate research into the cause, progression and treatment ...
... The fight against bone disorders that affect ... from an ultrasound device being developed by space ... early prediction of bone disorders such as osteoporosis ... Biomedical Research Institute (NSBRI) scientists are developing ...
... Inc. (NYSE: WLP ) announced today that ... Attorney General regarding the manner in which out-of-network reimbursement ... the Agreement with the Attorney General, WellPoint has agreed ... it uses in determining out-of-network reimbursement for certain products ...
... Researchers at Rhode Island Hospital have completed a ... measures during a possible flu pandemic. Their study focused ... individuals showing no symptoms (asymptomatic) or from individuals who ... The researchers call on the scientific community to better ...
Cached Medicine News:Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 2Health News:Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy 3Health News:PCAS: 2008 Results 2Health News:PCAS: 2008 Results 3Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 2Health News:Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain 3Health News:SCAN: Delivering Bone Disorder Diagnosis, Fracture Healing 2Health News:SCAN: Delivering Bone Disorder Diagnosis, Fracture Healing 3Health News:WellPoint Joins New York Attorney General in Creation of New Independent Database for Out-of-Network Reimbursement 2Health News:Study calls for increased research in flu transmission to prepare for pandemic flu outbreak 2
... catheter or instrument introduction. The dual ... peeled away and removed. The maximum ... to be introduced should be measured ... sheath. Supplied sterile in peel-open packages. ...
... Used percutaneously to direct a ... wire guide to a specific ... has an inner stainless steel ... to the catheter shaft. Supplied ...
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: